AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01960543
Drug: fentanyl 15 microg
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01228357
Drug: SSRI treated group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant administration of SSRI class for 12 weeks under therapeutic dose
Trial: NCT01228357
Drug: non-SSRI treated group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant administration of non-SSRI class for 12 weeks under therapeutic dose
Trial: NCT00723346
Drug: native L asparaginase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10000UI/m2, 14 infusions during 4 chemotherapy cycle
Trial: NCT01479595
Drug: QBX258
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QBX258 infusion, a combination of VAK694 and QAX576, was supplied to the Investigator as open label bulk medication. The planned dose of VAK694 (lyophilisate in vial, 150 mg/vial), was 3 mg/kg. The planned dose of QAX576 (lyophilisate in vial, 150 mg/vial), was 6 mg/kg.
Trial: NCT01479595
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo infusion was an equal volume of 5% dextrose for infusion and was provided by the clinical site.
Trial: NCT02255565
Drug: Very Low Dose Quillivant XR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral suspension dose once a day increasing to a 10mg dose
Trial: NCT02255565
Drug: Low Dose Quillivant XR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral suspension dose once a day increasing to a 20mg dose
Trial: NCT02255565
Drug: Moderate Dose Quillivant XR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral suspension dose once a day increasing to a 40mg dose
Trial: NCT02496845
Drug: VL#FIA3-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasoactive dual treatment (MH30-01 \& IS045-01)
Trial: NCT02177643
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsules
Trial: NCT02998905
Drug: Acetylsalicylic Acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid 81 mg/day
Trial: NCT02515045
Drug: TriMoxiVanc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: triamcinolone acetonide 15 mg / ml with moxifloxacin 1 mg/ml, vancomycin 10 mg/ml to be injected at time of cataract surgery.
Trial: NCT02515045
Drug: Prednisolone acetate 1%
RxNorm normalized name: PREDNISOLONE ACETATE 1% SUSP,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid to be started after surgery 1 drop QID for 2 weeks, tapered to BID for 2 weeks, and then discontinued.
Trial: NCT01429272
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg po bid for 6 weeks
Trial: NCT01429272
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo for minocycline and/or aspirin
Trial: NCT00825396
Drug: C-KAD Ophthalmic Solution
RxNorm normalized name: urea c-13 Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 drops applied daily for 150 days
Trial: NCT02156544
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01253265
Drug: LY2439821
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously
Trial: NCT01253265
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously
Trial: NCT00711802
Drug: Standard of Care (SOC)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02370095
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplied by the manufacturer and similar to the active drug but containing no Treprostinil
Trial: NCT00900146
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lyophilized cake will be reconstituted and then used to dilute the 25mg or 150mg solutions to make 5mg, 15mg and 50mg injections.
Trial: NCT00276094
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
Trial: NCT00378937
Drug: acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00378937
Drug: codeine phosphate
RxNorm normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00378937
Drug: dextropropoxyphene hydrochloride
RxNorm normalized name: Dextropropoxyphene hydrochloride
DrugBank: Dextropropoxyphene (DB00647)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02770807
Drug: Pooled Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDS processed autologous erythrocytes using a sodium chloride \[NaCl\] solution.
Trial: NCT03077698
Drug: progestin therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study will investigator the use of progestin therapy in conjunction with Sodium Cridanimod
Trial: NCT00690287
Drug: AZD6370
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral single doses a+b+c, o.d., suspension
Trial: NCT00690287
Drug: AZD6370
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral single dose, o.d., b.i.d. and q.i.d., suspension
Trial: NCT00690287
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04140201
Drug: Simvastatin 40mg
RxNorm normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drugs that lower lipid level
Trial: NCT02576665
Drug: Toca FC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toca FC is an extended-release formulation of flucytosine. Toca FC is supplied as 500 mg white, oblong tablets with TOCA FC embossed on one side and 500 embossed on the other side
Trial: NCT01239888
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 IU of intranasal placebo twice per day for 8 weeks, and a placebo (oral) for the 8 week trial
Trial: NCT02312219
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg folic acid once daily
Trial: NCT02312219
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo once weekly
Trial: NCT02312219
Drug: Low Dose Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: An anti-inflammatory drug
Trial: NCT00266838
Drug: Maxidex; Lacrystat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 times daily, for 20 weeks.
Trial: NCT02226198
Drug: Rosuvastatin 20mg
RxNorm normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Active drug will be taken taken orally, QD, either in the morning or in the evening
Trial: NCT02226198
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Will be taken taken orally, QD, either in the morning or in the evening
Trial: NCT00437450
Drug: Epoetin/Atra
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03888677
Drug: 5-FU, epirubicin and cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored dose escalation of epirubicin and cyclophosphamide.
Trial: NCT02654236
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of placebo, taken orally daily with water, approximately 30 minutes prior to breakfast for 4 weeks.
Trial: NCT02654236
Drug: 10 mg Obeticholic Acid (OCA)
RxNorm normalized name: obeticholic acid 10 MG
DrugBank: Obeticholic acid (DB05990)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily, approximately 30 minutes prior to breakfast for 4 weeks.
Trial: NCT01921218
Drug: Calcineurin inhibitor therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upon enrollment, wean calcineurin inhibitor (CNI) to target tacrolimus trough of 3-5 nanogram/milliliter (ng/ml)or equivalent cyclosporine trough. Upon initiation of hemodialysis, discontinue CNI therapy over 5 days.
Trial: NCT03172065
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous flluid
Trial: NCT01633203
Drug: epirubicin + cisplatin + capecitabine polychemotherapy
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: EPIRUBICIN (LKM)at a dose of 50 mg/m2 over 15 minutes is administered every 21 days.~CISPLATIN (LKM) at a dose of 60 mg/m2 over 4 hours is administered every 21 days. Patients must receive standardized hydration per protocol.~CAPECITABINE (Xeloda®) at a dose of 625 mg/m2 BID (i.e. 1250 mg/m2/day) 30 minutes after meals from day 1 to day 21 of every cycle of chemotherapy.~Antiemetic therapy:~* Dexamethasone 8 mg IV and Ondansetron (LKM) 8 mg IV o Granisetron (Kytril®) prior to chemotherapy~* Rescue Ondansetron (LKM) 8 mg IV will be given during 24-hour hospitalization in case of emesis~* Symptomatic antiemetic therapy with thiethylperazine will be prescribed.~Loperamide will be prescribed in case of diarrhea.
Trial: NCT00906139
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl dose: 0.05 mg
Trial: NCT00354107
Drug: therapeutic hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IT
Trial: NCT00354107
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT
Trial: NCT00162461
Drug: Phenytoin single dose (300 mg)
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02128243
Drug: S-1 de-escalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 30 mg/m² bid d1-14 q21d
Trial: NCT02128243
Drug: Chemotherapy by Investigator's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polychemotherapy administration as in induction therapy consists of a platinum and fluoropyrimidine compound as well as optional a taxane / an anthracycline compound.~Two-Drug combinations:~FLO / mod. FOLFOX-6; Cisplatin, S-1; Cisplatin, 5-FU; Cisplatin, Capecitabine (XP)~Three-drug combinations:~EOX/EOF FLOT
Trial: NCT00892203
Drug: BGG492
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00892203
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03529097
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 liters of 0.9% NaCl bag covered with black bag so the participant could not tell the fluids are not dripping to his vain
Trial: NCT00913809
Drug: Desipramine HCL 100 mg Tablets Cord Laboratories
RxNorm normalized name: desipramine
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00913809
Drug: Norpramin 100 mg Tablets Merrell Dow Pharmaceuticals, Inc
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01471418
Drug: PET/CT with 18-FDG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDG uptake
Trial: NCT01478841
Drug: polyphenol
RxNorm normalized name: Polyphenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules of 0.5 gram to be taken at the beginning of breakfast and dinner (2g/day) fructose : dose of 3 g/kg/day from D57 to D62 in the form of a 20% solution taken during the three main meals
Trial: NCT01478841
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules of 0.5 gram to be taken at the beginning of breakfast and dinner (2g/day) fructose : dose of 3 g/kg/day from D57 to D62 in the form of a 20% solution taken during the three main meals
Trial: NCT00504790
Drug: GSK923295
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-mitotic compound
Trial: NCT02763475
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60mg/kg by vein on day -6
Trial: NCT01611051
Drug: Drug: Pegylated rhG-CSF: 100µg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
Trial: NCT01611051
Drug: Pegylated rhG-CSF: 6mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were administered pegylated rhG-CSF 6mg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
Trial: NCT01611051
Drug: rhG-CSF 5ug/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were administered pegylated rhG-CSF 6 ug/kg/day from the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
Trial: NCT01156389
Drug: Pyramax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyramax (pyronaridine/artesunate) 180:60 mg (3 to 4 tablets once per day according to weight for 3 days).
Trial: NCT01715350
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * The drug will be taken with water within 30 minutes after breakfast and supper.~* 650mg/1 tablet, PO, 12weeks
Trial: NCT00367744
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for rosiglitazone
Trial: NCT00819377
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml normal saline by inhalation over 15 min
Trial: NCT00499655
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT02257385
Drug: UMEC/VI matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ELLIPTA DPI will be supplied with 30 doses (2 strips with 30 blisters per strip) where first strip contains lactose monohydrate and magnesium stearate 0.6% w/w of total drug product and second strip contains lactose monohydrate and magnesium stearate 1.0% w/w of total drug product
Trial: NCT03035253
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment will consist of OMP-305B83 and the FOLFIRI chemotherapy regimen.
Trial: NCT03035253
Drug: FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment will consist of OMP-305B83 and the FOLFOX chemotherapy regimen.
Trial: NCT03824275
Drug: 18F- DCFPyL PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A CT scan using a radioactive marker to better image tumors
Trial: NCT04371822
Drug: SnPP Protoporphyrin plus Sunlight exposure
RxNorm normalized name: SnPP Protoporphyrin
DrugBank: Tin protoporphyrin IX (DB16449)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SnPP Protoporphyrin plus Sunlight exposure
Trial: NCT04371822
Drug: SnPP Protoporphyrin plus Sunlight exposure
RxNorm normalized name: SnPP Protoporphyrin
DrugBank: Tin protoporphyrin IX (DB16449)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SnPP Protoporphyrin and Sunlight exposure
Trial: NCT04371822
Drug: Sulfonatoporphyrin(TPPS) plus Sunlight exposure.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfonatoporphyrin(TPPS) plus Sunlight exposure.
Trial: NCT01404013
Drug: ICS/LABA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 160µg and Formoterol 4.5µg, 1puff ,twice a day, for 8 weeks
Trial: NCT01567202
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temozolomide(TMZ), 200mg·m\^-2·d ×5 days，28 days every cycle. 6 cycles of TMZ are recommended.
Trial: NCT01567202
Drug: blank placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline that has the same appearance with DC vaccine.
Trial: NCT03835884
Drug: AR-13503 Implant 10.6 Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AR-13503 Implant 10.6 Dose (10.6 µg) administered as an intravitreal implant into a single eye
Trial: NCT03835884
Drug: AR-13503 Implant 21.2 Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AR-13503 Implant 21.2 Dose (21.2 µg) administered as intravitreal implants into a single eye
Trial: NCT03835884
Drug: AR-13503 42.4 Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AR-13503 Implant 42.4 Dose (42.4 µg) administered as intravitreal implants into a single eye
Trial: NCT03835884
Drug: AR-13503 63.6 Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AR-13503 Implant 63.6 Dose (63.6 µg) administered as intravitreal implants into a single eye
Trial: NCT00459693
Drug: [11C]PBR28
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00874406
Drug: folfox4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: folfox4 will be done within 28 days after liver resection
Trial: NCT02078102
Drug: Meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 mg tablets of Meloxicam will be taken orally in the morning, with or without food.
Trial: NCT02798991
Drug: GSK3179106
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is uncoated round or oblong tablet with 3 strengths viz;. 5, 25 and 100 mg. It is White to slightly colored tablet and will be administered orally
Trial: NCT02798991
Drug: Matched Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is uncoated round or oblong placebo tablet prepared to match actives across all strengths. It is White to slightly colored tablet and will be administered orally
Trial: NCT02133664
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo lipoic acid and placebo oil
Trial: NCT02833792
Drug: Human Mesenchymal Stem Cells and Lactated Riunger's Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration
Trial: NCT01617135
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00070252
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT02956850
Drug: RO7020531
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7020531 will be administered as per schedule specified in the respective arm.
Trial: NCT03177811
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
Trial: NCT01668641
Drug: GLPG0634
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01668641
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03833570
Drug: BBC oral spray
RxNorm normalized name: SNAIL, UNSPECIFIED 18.05 g in 40 g / TITANIUM DIOXIDE 3.6 g in 40 g / ZINC OXIDE 2.52 g in 40 g / ARBUTIN 0.8 g in 40 g / ADENOSINE 0.016 g in 40 g TOPICAL CREAM [SKIN79 SNAIL NUTRITION BBCREAM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthetics and anti-inflammatory agent
Trial: NCT03833570
Drug: Oracure gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical analgesic gel
Trial: NCT03515941
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 625 mg/m2 (Arm 1), 1000 mg/m2 (Arm 1), 750 mg/m2 by PO (Arm 2)
Trial: NCT03515941
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m2 by IV (Arm 1 \& Arm 2)
Trial: NCT02960646
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02606760
Drug: P-3073
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02606760
Drug: Vehicle of P-3073
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01560052
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention: Drug: Placebo~Original Cohort:~Matching placebo tablets, all the patients will receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.~Low Dose cohort:~Matching placebo will be given reducing over 6-9months. All the patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.~Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months after randomisation in the low dose cohort, for the prevention of severe PJP infection, unless there is a documented sulfa allergy
Trial: NCT02819960
Drug: Probio-Tec® BG-VCap-6.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each capsule contents: 2 lyophilized probiotic strains, total amount of minimum 2,7x10 9 CFU/cps, ratio LGG®: BB-12® = 50% : 50% (Culture percentages are based on cell concentration and are approximate) Lactobacillus rhamnosus GG® (ATCC 53103) Bifidobacterium animalis subsp. lactis BB-12® (DSM 15954) Additives: maltodextrin, microcrystalline cellulose, silicium dioxide, magnesium stearate
Trial: NCT02819960
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrin
Trial: NCT03340896
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU, 750 mg / m² / day administered in continuous infusion from D1 to D5 (or 120 hours)
Trial: NCT01048723
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were instructed to take RAD001 in the morning, at the same time each day.
Trial: NCT00787137
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphate-buffered saline